CD8A and chronic myelogenous leukemia, BCR-ABL1 positive: In addition, the level of PD-1+CD8+ TEMRA significantly increased in DN-CML (16.57%, P = 0.0083), TKI-F (18.73%, P = 0.0019), and Pre-MMR (17.32%, P = 0.0052) patients but returned to a normal level in some MMR patients (15.27%, P = 0.3686) when compared with HIs (7.94%) (Figure 2F).